Breaking News Instant updates and real-time market news.

EXPO

Exponent

$56.39

0.23 (0.41%)

, AKRX

Akorn

$2.77

-0.16 (-5.46%)

18:57
04/18/19
04/18
18:57
04/18/19
18:57

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Exponent (EXPO) up 4.5%. ALSO HIGHER: Akorn (AKRX) up 12.6% after getting FDA approval for Loteprednol Etabonate Ophthalmic.... Zosano Pharma (ZSAN) up 7.4% after disclosed stock purchase by CEO... Fastenal (FAST) up 3.1% after board approved stock split... Aphria (APHA) up 1.6% after receiving cannabis cultivation license in Germany. DOWN AFTER EARNINGS: Intuitive Surgical (ISRG) down 7.3%... People's United Financial (PBCT) down 1.9%. ALSO LOWER: Intersal (I) down 2.3% after disclosing "total loss of Intelsat 29e spacecraft due to anomaly... Eli Lilly (LLY) down 2.0%, Pfizer (PFE) down 1.0% after disclosing Phase 3 study of tanezumab met 2 of 3 co-primary endpoints. Movers as of 18:30ET.

EXPO

Exponent

$56.39

0.23 (0.41%)

AKRX

Akorn

$2.77

-0.16 (-5.46%)

ZSAN

Zosano Pharma

$3.41

-0.11 (-3.13%)

FAST

Fastenal

$71.08

0.95 (1.35%)

APHA

Aphria

$7.65

-0.165 (-2.11%)

ISRG

Intuitive Surgical

$528.04

3.29 (0.63%)

PBCT

People's United

$17.12

-0.21 (-1.21%)

I

Intelsat

$19.48

0.235 (1.22%)

LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

PFE

Pfizer

$39.37

-0.5 (-1.25%)

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 16

    May

  • 18

    May

  • 05

    Jun

EXPO Exponent
$56.39

0.23 (0.41%)

04/23/18
RHCO
04/23/18
NO CHANGE
Target $95
RHCO
Buy
Exponent price target raised to $95 from $84 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on Exponent to $95, saying he is encouraged by the company's Q1 earnings beat and its positive FY18 outlook. Sommer notes that the company's upgrade in its FY18 EBITDA margin view is driven by "robust demand levels from various industries", including consumer products, automotive, medical products, and energy. The analyst keeps his Buy rating, also citing the company's expansion into the "more lucrative" proactive services business.
07/20/18
RHCO
07/20/18
NO CHANGE
Target $56
RHCO
Buy
Exponent price target raised to $56 from $47.50 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on Exponent to $56 after its Q2 earnings beat along with its raised EBITDA margin guidance. Sommer says the "industry-focused sale teams" are driving market share gains in the "lucrative large proactive engagements", while the company's new CEO Catherine Corrigan also offered "crisp" and "insightful" answers on the earnings call. The analyst is keeping his Buy rating on Exponent, stating the company's underlying growth remains firm, while its focus on "cross-selling by forming industry-focused sales teams" should also allow it to capture market share.
09/12/18
BREN
09/12/18
INITIATION
Target $63
BREN
Buy
Exponent initiated with a Buy at Berenberg
Berenberg started Exponent with a Buy rating and $63 price target.
AKRX Akorn
$2.77

-0.16 (-5.46%)

12/07/18
CHLM
12/07/18
NO CHANGE
Target $11
CHLM
Buy
Craig-Hallum maintains Buy rating, $11 target on Akorn after Fresenius ruling
Craig-Hallum analyst Matt Hewitt said the Delaware Supreme Court ruling in favor of Fresenius (FSNUY) ends any hopes that a merger with Akorn (AKRX) will still occur, which may be a disappointment to some investors. However, it has been his view since the first ruling was announced that Akorn should be valued on a standalone basis. Akorn currently has a large pipeline of higher margin generics and the company's low-cost manufacturing facility in India has been idled due to the terms of the Fresenius agreement, but is likely to be brought online sometime in FY19 or FY20, Hewitt tells investors. He keeps a Buy rating and $11 price target on Akorn shares, which are down $1.34, or 24%, to $4.25 in afternoon trading.
12/10/18
PIPR
12/10/18
NO CHANGE
Target $9
PIPR
Overweight
Piper does not view Akorn as 'major fixer-upper,' keeps $9 target
Piper Jaffray analyst David Amsellem says he would not view Akorn (AKRX) as a "major fixer-upper" now that it is planning to move forward as a stand-alone company. Much of the pressure on EBITDA in recent years was a function of limited-competition products with brand-like margins, Amsellem tells investors in a research note. Further, the rest of Akorn's product portfolio appears to be stable, says the analyst. In addition, "high-quality" abbreviated new drug application approvals have been happening, "and that matters," argues Amsellem. He keeps an Overweight rating on Akorn with a $9 price target.
03/11/19
JMPS
03/11/19
NO CHANGE
JMPS
Market Perform
Akorn is currently fairly valued, says JMP Securities
Akorn's Q4 results were negatively impacted by manufacturing issues, and the company is dedicating 2019 to remediating the issues, JMP Securities analyst Donald Ellis tells investors in a post-earnings research note. The company also experienced increasing competition for multiple products and lower overall prices impacting revenues, the analyst adds. Ellis believes Akorn's new management team is equipped to expedite its manufacturing remediation and re-start new drug submissions and approvals. However, he finds the stock currently fairly valued and maintains a Market Perform rating on the name.
03/19/19
RHCO
03/19/19
INITIATION
Target $4
RHCO
Hold
Akorn initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert started Akorn with a Hold rating and $4 price target. The company is dealing with quality issues at key facilities that could delay new approvals and potentially impact on-market products, Gilbert tells investors in a research note. Further, he believes that while expectations have been reset, the stock is "not inexpensive relative to its peers."
ZSAN Zosano Pharma
$3.41

-0.11 (-3.13%)

06/28/18
06/28/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CBS (CBS) initiated with an Outperform at Imperial Capital. 2. Limoneira (LMNR) initiated with a Buy at Stifel. 3. Keryx (KERX) initiated with a Buy at H.C. Wainwright. 4. Zosano Pharma (ZSAN) initiated with a Buy at BTIG. 5. Gilead (GILD) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/18
BTIG
06/28/18
INITIATION
Target $19
BTIG
Buy
Zosano Pharma initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Zosano Pharma with a Buy rating and a price target of $19 after its M207 - "a promising, rapid-acting ADAM-based form of zolmitriptan completed a pivotal study with very positive results". Hazlett says the drug demonstrated comparable efficacy in the acute treatment of migraine comparable to injectable triptans and also appears to be superior to newer therapeutics in development. The analyst believes that M207 can have a "substantial role in difficult-to-treat well-established migraine", adding that the valuation on Zosano Pharma stock also appears to be "attractive".
02/21/19
BTIG
02/21/19
NO CHANGE
BTIG
Buy
BTIG boosts Zosano target to $19 on 'solid' migraine safety data
BTIG analyst Robert Hazlett raised his price target for Zosano Pharma to $19 and keeps a Buy rating on the shares. The stock in morning trading is up 95%, or $2.10, to $4.31. Zosano's 12-month safety study of Qtrypta, its novel acute migraine therapeutic, demonstrates "rapid, robust, and durable efficacy," Hazlett tells investors in a research note. He believes the study announced this morning should finalize the clinical requirements for a New Drug Application in Q4. The data continue to support Qtrypta's "meaningful potential" as an acute migraine treatment, particularly for those with nausea or with difficult-to-treat migraine, says Hazlett. He estimates Qtrypta's approval in 2020 with U.S. peak revenue of ~$300M. The analyst estimates Zosano's standalone net present value at $16.94 per share, and the company's potential as a takeover target boosts his price target to $19.
04/17/19
MAXM
04/17/19
INITIATION
Target $8
MAXM
Buy
Zosano Pharma initiated with a Buy at Maxim
Maxim analyst Anthony Vendetti initiated Zosano Pharma with a Buy rating and a price target of $8, citing the company's "innovative drug delivery platform" to be used initially in migraine treatments which he estimates to be about a $1B market. The analyst also points to Zosano Pharma's products' "superior clinical efficacy and safety profiles" as well as their "ease of use", anticipating the company to submit a New Drug Application with the FDA by Q4 of 2020.
FAST Fastenal
$71.08

0.95 (1.35%)

02/12/19
KEYB
02/12/19
DOWNGRADE
KEYB
Sector Weight
KeyBanc downgrades Fastenal on more balanced risk/reward profile
KeyBanc analyst Steve Barger downgraded Fastenal to Sector Weight from Overweight. The analyst continues to view the company as a "best-in-class" distributor with a "sizable first-mover advantage" in OnSite and Vending, but he finds the stock's risk/reward as more balanced near his prior price target of $62. At current levels, Fastenal is trading in line with its historical enterprise value to /EBITDA multiple as well as its historical premium to peers, Barger tells investors in a research note. Further, the analyst would not move his price target higher given the company's "tough comps against moderating cycle growth" and his view that distributor multiples are unlikely to return to historical levels.
04/15/19
NRCS
04/15/19
DOWNGRADE
NRCS
Neutral
Fastenal downgraded to Neutral on valuation at Northcoast
Northcoast analyst Ryan Cieslak downgraded Fastenal to Neutral from Buy citing valuation.
04/12/19
GDHS
04/12/19
DOWNGRADE
Target $270
GDHS
Underperform
Grainger downgraded to Underperform from Hold at Gordon Haskett
Gordon Haskett analyst John Inch downgraded Grainger (GWW) to Underperform from Hold and cut his price target to $270 from $300 due to his view of the risk that Grainger's U.S. sales significantly decelerate, driven by his analysis of web data. Considering his view that much of Grainger's share price appreciation in the past two years has likely been driven by U.S. results that surprised to the upside, Inch believes the stock's multiple could contract in the case of U.S. miss, he tells investors. The "lackluster" web traffic trends, at a minimum, are a sign that Grainger's on-line market share gains are no longer accelerating, said Inch, who also cites strong results from Fastenal (FAST).
02/12/19
02/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BHP Billiton (BHP) downgraded to Neutral from Buy at Goldman Sachs. 2. Gilead (GILD) downgraded to Neutral from Buy at Citi and to Market Perform from Outperform at Wells Fargo. 3. Cisco (CSCO) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst James Faucette saying Cisco's multiple has meaningfully expanded over the past 1.5 years as estimates and expectations have built in a likely benefit from security-driven networking. 4. Take-Two (TTWO) downgraded to Underperform from Market Perform at BMO Capital with analyst Gerrick Johnson saying that after a 2-year "hype machine" blast for its Red Dead Redemption 2 title and its "strong" premier, the buzz around the game has "dissipated markedly." 5. Fastenal (FAST) downgraded to Sector Weight from Overweight at KeyBanc with analyst Steve Barger saying he continues to view the company as a "best-in-class" distributor with a "sizable first-mover advantage" in OnSite and Vending, but he finds the stock's risk/reward as more balanced near his prior price target of $62. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
APHA Aphria
$7.65

-0.165 (-2.11%)

04/16/19
VERF
04/16/19
NO CHANGE
Target $8
VERF
Sell
Use Aphria results as guide and short Tilray shares, says Vertical Group
Vertical Group analyst Gordon Johnson tells investors to use Aphria's (APHA) fiscal Q3 results as a guide and build a short position in Tilray (TLRY). The analyst last week initiated coverage of Tilray with a Sell rating and $8 year-end price target. Despite expectations for growth in Canadian sales due to the growth expectations for the recreational cannabis market, Aphria's kilograms sold fell 22.7% quarter-over-quarter in the quarter reported yesterday, Johnson tells investors in an email to clients. The analyst maintains his negative bias on Tilray following Aphia's results. Shares of Tilray are up 54c to $49.78 in early trading.
03/14/19
COWN
03/14/19
NO CHANGE
COWN
Narrow U.S. cannabis bills have better prospects than broad ones, says Cowen
Cowen analyst Jaret Seiberg said it is hard for him to see a scenario in the 116th Congress in which Senate Majority Leader Mitch McConnell holds a vote on legislation to fully legalize cannabis, as too many senators see no political upside for McConnell to schedule such a vote. Given this view, Seiberg believes that prospects are better for narrower bills that could get attached to spending packages and other measures than for broader bills that would legalize recreational use. Of the narrower bills introduced in the U.S. so far, Seiberg believes the SAFE Act on cannabis banking has the best shot before the 2020 election. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
02/21/19
02/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. At Home Group (HOME) initiated with a Hold at Loop Capital. 2. Harmonic (HLIT) initiated with a Buy at Stifel. 3. Atkore (ATKR) initiated with a Neutral at Credit Suisse. 4. BioTime (BTX) and Verrica Pharmaceuticals (VRCA) were initiated with a Buy at H.C. Wainwright. 5. Aphria (APHA), KushCo Holdings (KSHB), and HEXO Corp (HEXO) were initiated with a Buy at Seaport Global, while Canopy Growth (CGC), Aurora Cannabis (ACB), and Tilray (TLRY) were initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/21/19
GHSC
02/21/19
INITIATION
Target $18
GHSC
Buy
Aphria initiated with a Buy at Seaport Global
Seaport Global analyst Brett Hundley initiated Aphria with a Buy rating and $18 price target, citing its positioning as a low-cost Canadian licensed producer and its move to establish broad-based international relationships.
ISRG Intuitive Surgical
$528.04

3.29 (0.63%)

04/01/19
DBAB
04/01/19
INITIATION
Target $630
DBAB
Buy
Intuitive Surgical initiated with a Buy at Deutsche Bank
Deutsche Bank started Intuitive Surgical with a Buy rating and $630 price target.
04/02/19
DBAB
04/02/19
INITIATION
Target $630
DBAB
Buy
Deutsche sees 'substantial' growth runway for Intuitive Surgical, starts at Buy
Deutsche Bank analyst Imron Zafar last night initiated coverage of Intuitive Surgical with a Buy rating and $630 price target. Intuitive is the dominant global leader in robotic surgery and one of the premier medtech growth stories, Zafar tells investors in a research note. Further, the analyst believes a "still-underpenetrated" worldwide surgery market leaves "substantial runway for continued robust sales growth."
04/02/19
04/02/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Buy at Cross Research and a Sell at Seaport Global. 2. Dow Inc. (DOW) initiated with an Outperform at BMO Capital and Credit Suisse, an Overweight at Morgan Stanley, as well as a Buy at Deutsche Bank and BofA/Merrill. 3. Sonos (SONO) initiated with a Buy at DA Davidson. 4. Q2 Holdings (QTWO) initiated with an Outperform at William Blair. 5. Intuitive Surgical (ISRG) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/19
CANT
04/05/19
NO CHANGE
Target $620
CANT
Overweight
Cantor sees 'several reasons' for why Intuitive Surgical momentum will continue
After attending the Society of American Gastrointestinal and Endoscopic Surgeons meeting, where Intuitive Surgical hosted an analyst event, Cantor Fitzgerald analyst Craig Bijou reiterates an Overweight rating on the shares with a $620 price target. The analyst sees "several reasons" to believe that Intuitive Surgical's momentum should continue, including "rapid" adoption of robotic hernia repair and robotic penetration expanding across a broad array of general surgery procedures. Intuitive Surgical is "years ahead of its competition in developing an intelligent surgery system, and its integrated ecosystem and vast data collection should help protect its lead," Bijou tells investors in a research note.
PBCT People's United
$17.12

-0.21 (-1.21%)

06/27/18
KBWI
06/27/18
UPGRADE
Target $37
KBWI
Outperform
First Connecticut upgraded to Outperform with $37 target at Keefe Bruyette
Keefe Bruyette analyst Damon DelMonte upgraded First Connecticut Bancorp (FBNK) to Outperform from Market Perform and raised his price target for the shares to $37 from $29. The analyst aligned his target and valuation with People's United Financial (PBCT) as a result of the pending merger between the two banks.
01/10/19
LEHM
01/10/19
NO CHANGE
LEHM
Barclays upgrades Mid-Cap Banks industry to Positive from Neutral
Barclays analyst Matthew Keating upgraded his view on the U.S. Mid-Cap Banks industry to Positive from Neutral. There seems to be a lot less enthusiasm for the banks this year, Keating tells investors in a research note. The focus this year is on rising trade tensions, slowing global growth, and chance of a recession, says the analyst. However, he believes the slide in bank stock sentiment creates opportunities for investors "willing to withstand some volatility in the near term." Along with the sector, Keating upgraded Synovus Financial (SNV) and Texas Capital (TCBI) to Overweight from Equal Weight and Bank OZK (OZK) and People's United Financial (PBCT) to Equal Weight from Underweight. Based on his relative ratings system, he downgraded Prosperity Bancshares (PB) to Equal Weight from Overweight and New York Community Bancorp (NYCB) to Underweight from Equal Weight.
01/10/19
LEHM
01/10/19
UPGRADE
Target $18
LEHM
Equal Weight
People's United upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Matthew Keating upgraded People's United Financial to Equal Weight while lowering his price target for the shares to $18 from $20.
12/20/18
FIGP
12/20/18
INITIATION
FIGP
Outperform
People's United initiated with an Outperform at Fig Partners
Fig Partners analyst David Bishop initiated People's United with an Outperform.
I Intelsat
$19.48

0.235 (1.22%)

04/03/19
JPMS
04/03/19
UPGRADE
Target $27
JPMS
Overweight
JPMorgan upgrades Intelsat to Overweight ahead of expected spectrum sales
JPMorgan analyst Philip Cusick upgraded Intelsat to Overweight from Neutral with an unchanged price target of $27. The stock has declined 28% year-to-date and 38% since February 27 when a "slew of headlines all but halted" the C-Band Alliance's momentum in D.C., Cusick tells investors in a research note. However, after being overly-optimistic in the fall, the market is now "underpricing the likelihood" of Intelsat and the C-Band Alliance eventually selling spectrum and "reaping substantial proceeds," says the analyst. Cusick believes the alliance still has the support of key decision makers at the Federal Communications Commission and that some version of a market-based approach is the most likely path to get C-Band spectrum into the hands of wireless carriers in the next five years.
04/03/19
04/03/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Urban Outfitters (URBN) upgraded to Buy from Neutral at DA Davidson with analyst John Morris saying the data showcase the company's "green shoots in improving pricing architecture at the Anthropologie division with stronger pricing and lower markdown cadence at the Urban division." 2. Intelsat (I) upgraded to Overweight from Neutral at JPMorgan with analyst Philip Cusick saying the stock has declined 28% year-to-date and 38% since February 27 when a "slew of headlines all but halted" the C-Band Alliance's momentum in D.C. 3. e.l.f. Beauty (ELF) upgraded to Buy from Hold at Jefferies with analyst Stephanie Wissink saying he believes the company's improved merchandising focus will drive a "meaningful reversal" in sales trends. 4. Enterprise Products (EPD) upgraded to Buy from Neutral at Goldman Sachs with analyst Michael Lapides citing the company's improving cash flow, exposure to key themes that include a "leading position in crude oil and NGL exports," and its position as "one of the more integrated infrastructure portfolios within the sector," extending its footprint "further downstream than most midstream companies." 5. CommScope (COMM) upgraded to Strong Buy from Outperform at Raymond James with analyst Simon Leopold saying he believes the earnings accretion from the pending Arris (ARRS) acquisition is underappreciated and will provide at least 40% accretion versus management's forecast for over 30% and analyst estimates of 25%-43%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/19
GSCO
04/17/19
NO CHANGE
GSCO
Sprint, T-Mobile headlines positive for Dish, Intelsat, says Goldman Sachs
Goldman Sachs analyst Brett Feldman, while taking no view on the outcome of the proposed merger between Sprint (S) and T-Mobile (TMUS), laid out his thoughts for other industry participants following the Wall Street Journal's report that the Department of Justice is unlikely to approve the deal as currently structured. The analyst believes investors will initially see the headlines as negative for the other major wireless carriers, namely AT&T (T) and Verizon (VZ), since they "create uncertainty over long-term industry structure." Further, investors will initially see these headlines as a slight positive for tower operators American Tower (AMT), Crown Castle (CCI) and SBA Communications (SBAC) as they "imply less risk of material cell site decommissioning," Feldman told investors earlier in a research note. The analyst also thinks investors will view the Journal's report as positive for owners of excess spectrum such as Dish (DISH) and Intelsat (I) and a slight positive for cable operators like Altice USA (ATUS), Charter (CHTR) and Comcast (CMCSA).
04/03/19
JPMS
04/03/19
UPGRADE
Target $27
JPMS
Overweight
Intelsat upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Philip Cusick upgraded Intelsat to Overweight from Neutral with a $27 price target. The analyst a C-band spectrum sale as the most likely course for the company.
LLY Eli Lilly
$115.20

-1.23 (-1.06%)

04/11/19
GUGG
04/11/19
DOWNGRADE
GUGG
Neutral
Guggenheim sees limited upside for Eli Lilly, downgrades to Neutral
As previously reported, Guggenheim analyst Seamus Fernandez downgraded Eli Lilly (LLY) to Neutral from Buy, stating that while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. Though he still thinks Eli Lilly has "the best long-term growth profile in US Pharma," that growth is the broad consensus view, said Fernandez, who removed his price target on the stock but estimates the fair value to be in the range of $125-$135 per share.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
04/11/19
GUGG
04/11/19
DOWNGRADE
GUGG
Neutral
Eli Lilly downgraded to Neutral from Buy at Guggenheim
04/11/19
04/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Chipotle (CMG) downgraded to Hold from Buy at Jefferies with analyst Andrew Barish saying after rallying 65% in Q1, Chipotle's valuation is full and reflects improved visibility for "powerful" same-store-sales and margin drivers. 2. Eli Lilly (LLY) downgraded to Neutral from Buy at Guggenheim with analyst Seamus Fernandez saying while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. 3. U.S. Steel (X) downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners citing worse near-term U.S. market conditions than she anticipated. 4. Keurig Dr Pepper (KDP) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying she sees a negative risk-reward despite a "well telegraphed" Q1 earnings beat on strong pricing at heritage Dr. Pepper Snapple. 5. Waste Management (WM) downgraded to Hold from Buy at Stifel with analyst Michael Hoffman saying he factors in incrementally weaker paper prices and the impact of wet weather. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$39.37

-0.5 (-1.25%)

01/31/19
01/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Neutral at Credit Suisse and to Buy from Hold at Argus. 2. Tiffany (TIF) upgraded to Overweight from Neutral at Atlantic Equities with analyst Daniela Nedialkova saying the pullback has been largely driven by macro concerns while fundamentals of the brand are strong and preliminary FY19 guidance is conservative. 3. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. Geron (GERN) upgraded to Buy from Neutral at B. Riley FBR with analyst George Zavoico saying he believes investors should focus on the pivotal Phase III trial of imetelstat. 5. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Dana Telsey saying the company's improving sakes, combined with ongoing margin expansion, should bolster its earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
LEHM
02/26/19
NO CHANGE
LEHM
Galapagos weakness could be tied to Pfizer safety alert, says Barclays
Barclays believes the weakness today in Galapagos NV (GLPG) could be attributed to, at least in part, the FDA's safety communication on Pfizer's (PFE) post-marketing study of 10mg daily Xeljanz. Competitor safety issues with higher dose JAK inhibitors was a major focus of Galapagos' post-earnings conference call last week, Barclays tells investors in a research note. Galapagos management, while limited in what it can say pending the data, seems to believe they can get both doses approved, Barclays contends. Further, the firm points out that the company has received no communication and sees no reason to conclude that the FDA has determined that thromboembolic events are a class effect of the JAKs. Shares of Galapagos are down 1.5%, or $1.45, to $97.28 in late morning trading.
02/20/19
02/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) resumed with a Neutral from Sell at Citi with analyst Andrew Baum saying the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. 2. Transocean (RIG) and Diamond Offshore (DO) were upgraded to Overweight from Underweight at Barclays. 3. American Axle (AXL) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy citing progress with restructuring, GM's (GM) truck cycle, and balance sheet deleveraging. 4. Credit Suisse (CS) upgraded to Hold from Sell at Berenberg. 5. Ipsen (IPSEY) upgraded to Neutral from Sell at Goldman Sachs with analyst Diana Na citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/19
SBSH
02/20/19
UPGRADE
Target $41
SBSH
Neutral
Pfizer resumed with a Neutral from Sell at Citi
Citi analyst Andrew Baum resumed coverage of Pfizer following a period of restriction and upgraded the shares to Neutral from Sell. He also boosted his price target for the shares to $41 from $37. The analyst says the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. He believes management action on business development, cost saving or moves to better monetize Pfizer's Established Product business are likely near-term drivers of the stock.

TODAY'S FREE FLY STORIES

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.